Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Melanoma: HELP
Articles by Marc Pracht
Based on 3 articles published since 2008
||||

Between 2008 and 2019, M. Pracht wrote the following 3 articles about Melanoma.
 
+ Citations + Abstracts
1 Guideline [Treatment of patients with inoperable stage III or stage IV melanoma. Société française de dermatologie]. 2018

Guillot, B / Charles, J / Jeudy, G / Cupissol, D / Dupuy, A / Dutriaux, C / Gangloff, D / Magne, N / Mirabel, X / M'Sadek, A / Pracht, M / Sichel, C / Do Outeiro, G. ·Département de dermatologie, hôpital Saint-Éloi, CHU de Montpellier, 34295 Montpellier, France. Electronic address: b-guillot@chu-montpellier.fr. · CHU de Grenoble, 38700 Grenoble, France. · CHU de Dijon, 21000 Dijon, France. · Institut du Cancer de Montpellier, 34298 Montpellier, France. · CHU de Rennes, 35000 Rennes, France. · CHU de Bordeaux, 33000 Bordeaux, France. · Institut universitaire du cancer de Toulouse, 31100 Toulouse, France. · Institut de cancérologie de la Loire, 42270 Saint-Priest-en-Jarez, France. · Centre Oscar-Lambret, 59000 Lille, France. · Centre Eugène-Marquis, 35000 Rennes, France. · 13470 Carnoux en Provence, France. · Institut national du cancer de Boulogne-Billancourt, 92100 Boulogne-Billancourt, France. ·Ann Dermatol Venereol · Pubmed #29703640.

ABSTRACT: -- No abstract --

2 Article Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma. 2015

Pracht, M / Mogha, A / Lespagnol, A / Fautrel, A / Mouchet, N / Le Gall, F / Paumier, V / Lefeuvre-Plesse, C / Rioux-Leclerc, N / Mosser, J / Oger, E / Adamski, H / Galibert, M-D / Lesimple, T. ·Service d'Oncologie Médicale, Centre Eugene Marquis, Rennes, France. · Brittany Melanoma Network, GRoupe Ouest Mélanome (GROUM), Rennes, France. · Gene Expression and Oncogenesis Team, Institut de Génétique et Developement de Rennes, CNRS UMR6290, Rennes, France. · CHU Pontchaillou, Université Européenne de Bretagne, Rennes, France. · CHU Pontchaillou, Service de Génétique Moléculaire et Génomique des Cancers, Rennes, France. · SFR Biosit UMS CNRS 3480/US INSERM 018, Rennes, France. · Service d'Anatomopathologie, CHU Pontchaillou, Rennes, France. · Laboratoire d'Anatomopathologie Atalante, Rennes, France. · Centre d'Investigations Cliniques et Unité de Pharmacologie et de Pharmaco-épidémiologie, Rennes, France. · CHU Pontchaillou, Service de Dermatologie, Rennes, France. ·J Eur Acad Dermatol Venereol · Pubmed #25623140.

ABSTRACT: BACKGROUND: Mutations of BRAF, NRAS and c-KIT oncogenes are preferentially described in certain histological subtypes of melanoma and linked to specific histopathological features. BRAF-, MEK- and KIT-inhibitors led to improvement in overall survival of patients harbouring mutated metastatic melanoma. OBJECTIVES: To assess the prevalence and types of BRAF, NRAS, c-KIT and MITF mutations in cutaneous and mucous melanoma and to correlate mutation status with clinicopathological features and outcome. METHODS: Clinicopathological features and mutation status of 108 samples and of 98 consecutive patients were, respectively, assessed in one retrospective and one prospective study. Clinicopathological features were correlated with mutation status and the predictive value of these mutations was studied. RESULTS: This work identified significant correlations between BRAF mutations and melanoma occurring on non-chronic sun-damaged skin and superficial spreading melanoma (P < 0.05) on one hand, and between NRAS mutations and nodular melanoma (P < 0.05) on the other hand. Younger age (P < 0.05), microscopic (P < 0.05) and macroscopic (P < 0.05) lymphatic involvement at diagnosis of primary melanoma were significantly linked to BRAF mutations. A mutated status was a positive predictive factor of a response to BRAF inhibitors (OR = 3.44). Mutated melanoma showed a significantly (P = 0.038) higher objective response rate to cytotoxic chemotherapy (26.3%) than wild-type tumours (6.7%). CONCLUSION: Clinical and pathological characteristics of the primary melanoma differed between wild-type and BRAF- or NRAS-mutated tumours. Patients with BRAF-mutated tumours were younger at diagnosis of primary melanoma. Patients carrying mutations showed better responses better to specific kinase inhibitors and interestingly also to systemic cytotoxic chemotherapy.

3 Article Metastatic melanoma: results of 'classical' second-line treatment with cytotoxic chemotherapies. 2014

Perrin, Christophe / Pracht, Marc / Talour, Karen / Adamski, Henri / Cumin, Isabelle / Porneuf, Marc / Talarmin, Marie / Mesbah, Habiba / Audrain, Odile / Moignet, Aline / Lefeuvre-Plesse, Claudia / Lesimple, Thierry. ·Department of Medical Oncology, Centre Régional de Lutte Contre le Cancer Eugène Marquis , Rennes , France. ·J Dermatolog Treat · Pubmed #22632465.

ABSTRACT: BACKGROUND: Metastatic melanoma is one of the most aggressive tumours, with a median survival that does not exceed 12 months. None of the cytotoxic first-line therapies have shown survival benefit in randomised clinical trials. OBJECTIVE: To describe clinical benefit of second-line cytotoxic chemotherapy in the second line of treatment for metastatic melanoma. METHODS: In a retrospective study, we analyse the outcome of patients with metastatic melanoma who had received two lines or more of cytotoxic treatments in four French dermato-oncology departments between 1999 and 2009. RESULTS: We describe the outcomes for 109 patients. Most of these patients received dacarbazine for the first line of chemotherapy and fotemustine for the second line of chemotherapy (67.0 and 64.2%, respectively). A clinical benefit was observed in 24.1% of the patients and overall survival was 4.1 months after the second-line treatment. At least 23.8% of patients suffered from grade 3 or 4 toxicities. The presence of more than two sites of metastasis and an M1c staging according to the AJCC classification represented negative predictive factors of clinical benefit. CONCLUSION: This study shows the modest benefit of a second line of cytotoxic chemotherapy in a nonselected population. If eligible, these patients should be proposed for ongoing clinical trials or for targeted therapies.